Close this search box.

Deals report: Lilly acquires Morphic, GSK gets full rights for mRNA vaccines from CureVac


Plus: Iaso gets full rights to Fucaso from Innovent, and updates from Genexine, EPD, Pentixapharm and Glycotope

By Gunjan Ohri, Data Content Analyst 

July 8, 2024 11:23 PM UTC

At least five deals were announced in the past seven days, including Eli Lilly’s $3.2 billion acquisition of Morphic, and GSK gaining full rights of mRNA vaccines from CureVac. 

Eli Lilly and Co. (NYSE:LLY) acquired Morphic Holding Inc. (NASDAQ:MORF), an oral integrin therapies company for $57 per share, a 79% premium over Friday’s close, valuing the deal at nearly $3.2 billion. Morphic’s lead program, MORF-057, is in Phase II studies for ulcerative colitis and Crohn’s disease.